An announcement from EVE Health Group Limited ( (AU:EVE) ) is now available.
EVE Health Group Limited has announced its acquisition of Nextract Pty Ltd, an Australian biotech firm specializing in novel pharmaceutical and nutraceutical delivery systems. This strategic move allows EVE to enter the $5.3 billion erectile dysfunction market and the $10.9 billion dysmenorrhea market with Nextract’s innovative, alcohol-free, orally dissolvable strips and chewable formats. The acquisition is valued at $3 million in equity, supported by a $1.5 million capital raising, and aims to expedite EVE’s entry into regulated markets, leveraging streamlined regulatory pathways in Australia. The acquisition is expected to enhance EVE’s market positioning, open new revenue streams, and offer high-margin potential through proprietary IP, with commercial launch targeted for Q4 2025.
More about EVE Health Group Limited
EVE Health Group Limited, listed on the ASX as EVE, is a company transitioning from a natural wellness focus to a broader health platform targeting regulated pharmaceutical, nutraceutical, and clinical segments. The company is enhancing its technical capabilities in formulation, bioavailability, and IP development, positioning itself at the intersection of natural medicine, regulatory science, and innovative delivery technology.
Current Market Cap: A$5.27M
Learn more about EVE stock on TipRanks’ Stock Analysis page.